• In recent weeks, Merck & Co., Inc. reported first-quarter 2026 results with US$16,286 million in sales, a net loss of US$4,240 million driven by acquisition-related charges, raised full-year sales guidance to US$65.8–67.0 billion, and expanded its oncology footprint through new Keytruda-focused collaborations and upcoming scientific presentations.
• These updates highlight how Merck is using its oncology franchise, particularly Keytruda combination trials and a broader late-stage pipeline, to offset near-term earnings volatility while preparing for future patent expiries.
• With Merck lifting 2026 sales guidance and broadening Keytruda collaborations, we’ll now examine how this reshapes the company’s investment narrative.

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Merck Investment Narrative Recap

To own Merck today, you need to believe its expanding oncology and vaccine portfolio can gradually reduce reliance on KEYTRUDA while absorbing near term earnings noise from one off acquisition charges. The latest collaborations and ASCO data do not change the key near term catalyst, which remains delivery on Merck’s late stage pipeline, nor the biggest risk, which is eventual KEYTRUDA loss of exclusivity and whether new products can sufficiently backfill that revenue.

The most relevant recent update is Merck’s clinical trial collaboration with Erasca on ERAS-0015 plus KEYTRUDA in RAS mutant solid tumors, alongside positive Phase 2 combination data with Inhibrx’s INBRX-106. These partnerships build on Merck’s guidance increase to US$65.8–67.0 billion of 2026 sales and show how external oncology alliances are being used to deepen the KEYTRUDA franchise as patents age.

Yet beneath the oncology progress, investors should be aware of how pricing pressure and future biosimilars could interact with Merck’s heavy dependence on KEYTRUDA...

Merck's narrative projects $72.0 billion in revenue and $24.3 billion in earnings by 2028.

Uncover how Merck's forecasts yield a $124.88 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming only about 3 percent annual revenue growth to roughly US$71 billion by 2029 and earnings of about US$20 billion, which is far more cautious than consensus around Merck’s pipeline and KEYTRUDA combinations, so this quarter’s oncology news could push those views closer together or widen the gap depending on how you think the data and deals really change the story.

Explore 11 other fair value estimates on Merck - why the stock might be worth 10% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.